Medidata Solutions Inc (NASDAQ:MDSO) CFO Rouven Bergmann sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the chief financial officer now owns 88,862 shares of the company’s stock, valued at approximately $6,664,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
MDSO stock opened at $77.21 on Friday. The company has a market cap of $4.74 billion, a P/E ratio of 90.84, a price-to-earnings-growth ratio of 4.58 and a beta of 1.30. Medidata Solutions Inc has a fifty-two week low of $59.60 and a fifty-two week high of $88.87. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.52 and a quick ratio of 2.52.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 18th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.06. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The firm had revenue of $163.41 million during the quarter, compared to analysts’ expectations of $162.09 million. During the same quarter in the previous year, the business earned $0.33 earnings per share. The firm’s revenue was up 17.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Medidata Solutions Inc will post 0.85 earnings per share for the current fiscal year.
MDSO has been the subject of several recent analyst reports. BidaskClub upgraded Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 16th. ValuEngine upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. Royal Bank of Canada decreased their target price on Medidata Solutions to $91.00 and set an “outperform” rating for the company in a research note on Tuesday, September 25th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Finally, Piper Jaffray Companies decreased their target price on Medidata Solutions from $96.00 to $93.00 in a research note on Thursday, October 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $85.10.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/12/02/rouven-bergmann-sells-10000-shares-of-medidata-solutions-inc-mdso-stock.html.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.